"The unusually long time that they have spent considering the drug suggests that this has not been an easy or straightforward decision," said psychiatrist Robert Howard at University College London in a statement to the UK Science Media Centre.
"Emotions are really high here," says Christian Haass, a biochemist at the Ludwig Maximilian University in Munich, Germany, who disagrees with the decision. "It's the first disease-modifying drug we have in more than 30 years."
Others applaud the EMA and say that while the drug did effectively lower amyloid levels in the brain, whether the reduction in cognitive decline is substantial enough to warrant its usage remains an open question.
[
Collection
]
[
|
...
]